Note: The contents of this blog are for informational purposes only and should not be construed as medical advice or substitute for professional care. For medical emergencies, dial 911!
European approval sought for new liver cancer drug
Posted Jun 21st 2007 3:20PM by Brian White
Filed under: Drug, Liver Cancer
A newer drug called Nexavar, used for the treatment of hepatocellular carcinoma cancer, is being marketed by Bayer and Onyx Pharmaceuticals in Europe to be approved for an officially-sanctioned treatment of liver cancer.
Although Nexavar is being used in 50 countries for kidney cancer, the drug is now being described as
a possible treatment for advanced liver cancer, it is now being suggested by both pharmaceutical companies for the treatment of liver cancer in Europe, with an application as a supplemental new drug being sent to the FDA sometime this summer, according to reports.
The summary phase 3 trial data concluded that Nexavar extended overall survival by 44 percent in patients with hepatocellular carcinoma compared to a placebo treatment. In addition, no additional side effects were noticed between Nexavar and placebo treatment patients.
Tags: liver cancer, liver cancer drug, LiverCancer, LiverCancerDrug
Please keep your comments relevant to this blog entry. Email addresses are never displayed, but they are required to confirm your comments.
When you enter your name and email address, you'll be sent a link to confirm your comment, and a password. To leave another comment, just use that password.
To create a live link, simply type the URL (including http://) or email address and we will make it a live link for you. You can put up to 3 URLs in your comments. Line breaks and paragraphs are automatically converted — no need to use <p> or <br> tags.
